• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据年龄组比较自体动静脉瘘和人工动静脉移植物的血管通畅率和患者生存率。

Comparison of vascular access patency and patient survival between native arteriovenous fistula and synthetic arteriovenous graft according to age group.

机构信息

Department of Radiology, The Catholic University of Korea School of Medicine/ St. Vincent's Hospital, Suwon, Republic of Korea.

Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea School of Medicine, Seoul, Republic of Korea.

出版信息

Hemodial Int. 2020 Jul;24(3):309-316. doi: 10.1111/hdi.12836. Epub 2020 May 5.

DOI:10.1111/hdi.12836
PMID:32372545
Abstract

INTRODUCTION

Arteriovenous fistula (AVF) is historically known to be the ideal option for vascular access (VA) for hemodialysis compared with arteriovenous graft (AVG). However, this approach has been recently questioned in the aging population because of their poor vessel quality and multiple comorbidities.

METHODS

Data from a total of 2200 patients from the VA category of The Catholic Medical Center nephrology registry from March 2009 to February 2017 were analyzed. We compared VA patency and patient survival between two groups, AVF and AVG, according to age.

FINDINGS

Compared with the AVG group, survival benefit in the AVF group continued even in patients ≥80 years. In the whole population, all the primary patency (PP), primary-assisted patency (PAP), and secondary patency (SP) measures were superior in the AVF group. With regard to subgroups, PP was comparable between the two groups in patients ≥65 years, whereas PAP and SP were superior in the AVF group even in septuagenarian patients who are from 70 to 79 years old. In patients ≥80 years, all the patency measures were comparable between the two groups. When the separate comparison of lower-arm AVF (or upper-arm AVF) and AVG, lower-arm AVF failed to demonstrate its superiority in any kind of patency in septuagenarian patients compared with AVG, whereas upper-arm AVF demonstrated its superiority in PAP and SP in septuagenarian patients. However, even upper-arm AVF failed to demonstrate its superiority in any kind of patency in patients ≥80 years.

DISCUSSION

Arteriovenous fistula if using upper-arm vessel showed the superior VA patency up to septuagenarian patients, whereas, in HD patients ≥80 years, AVF and AVG were comparable in VA patency.

摘要

介绍

与动静脉移植物 (AVG) 相比,动静脉瘘 (AVF) 历史上被认为是血液透析血管通路 (VA) 的理想选择。然而,由于血管质量差和多种合并症,这种方法在老年人群中最近受到质疑。

方法

分析了 2009 年 3 月至 2017 年 2 月天主教医疗中心肾脏病登记处 VA 类别中 2200 名患者的数据。我们根据年龄比较了 AVF 和 AVG 两组的 VA 通畅性和患者生存率。

结果

与 AVG 组相比,AVF 组的生存获益在≥80 岁的患者中仍然存在。在整个人群中,AVF 组的所有主要通畅率 (PP)、主要辅助通畅率 (PAP) 和次要通畅率 (SP) 均优于 AVG 组。就亚组而言,≥65 岁患者两组的 PP 相当,而≥70 岁(70-79 岁)患者的 PAP 和 SP 优于 AVF 组。≥80 岁的患者,两组的所有通畅率均相当。当分别比较下臂 AVF(或上臂 AVF)和 AVG 时,与 AVG 相比,下臂 AVF 在≥70 岁患者中任何类型的通畅率均无优势,而上臂 AVF 在≥70 岁患者中 PAP 和 SP 具有优势。然而,即使是在上臂 AVF 中,在≥80 岁的患者中也没有任何类型的通畅率具有优势。

讨论

在上臂血管使用动静脉瘘显示出直至 70 岁患者更好的 VA 通畅率,而在≥80 岁的 HD 患者中,AVF 和 AVG 在 VA 通畅率方面相当。

相似文献

1
Comparison of vascular access patency and patient survival between native arteriovenous fistula and synthetic arteriovenous graft according to age group.根据年龄组比较自体动静脉瘘和人工动静脉移植物的血管通畅率和患者生存率。
Hemodial Int. 2020 Jul;24(3):309-316. doi: 10.1111/hdi.12836. Epub 2020 May 5.
2
Comparison of Outcomes with Arteriovenous Fistula and Arteriovenous Graft for Vascular Access in Hemodialysis: A Prospective Cohort Study.动静脉内瘘与动静脉移植物用于血液透析血管通路的结局比较:一项前瞻性队列研究
Am J Nephrol. 2016;43(2):120-8. doi: 10.1159/000444889. Epub 2016 Mar 30.
3
Assessment of Use of Arteriovenous Graft vs Arteriovenous Fistula for First-time Permanent Hemodialysis Access.评估动静脉移植物与动静脉瘘在首次永久性血液透析通路中的应用。
JAMA Surg. 2019 Sep 1;154(9):844-851. doi: 10.1001/jamasurg.2019.1736.
4
An Outcomes Comparison of Native Arteriovenous Fistulae, Polytetrafluorethylene Grafts, and Cryopreserved Vein Allografts.自体动静脉内瘘、聚四氟乙烯移植物和冷冻保存静脉同种异体移植物的疗效比较
Ann Vasc Surg. 2015 Nov;29(8):1642-7. doi: 10.1016/j.avsg.2015.07.009. Epub 2015 Aug 28.
5
Costs Attributable to Arteriovenous Fistula and Arteriovenous Graft Placements in Hemodialysis Patients with Medicare coverage.医疗保险覆盖的血液透析患者动静脉瘘和动静脉移植物置管所导致的成本。
Am J Nephrol. 2019;50(4):320-328. doi: 10.1159/000502507. Epub 2019 Aug 21.
6
Evaluation of outcomes with permanent vascular access in an elderly Korean population based on the National Health Insurance Service database.基于韩国国民健康保险服务数据库评估老年人群中永久性血管通路的结局。
Hemodial Int. 2023 Jul;27(3):249-258. doi: 10.1111/hdi.13077. Epub 2023 Mar 21.
7
Patients started on hemodialysis with tunneled dialysis catheter have similar survival after arteriovenous fistula and arteriovenous graft creation.开始使用带隧道的透析导管进行血液透析的患者,在动静脉内瘘和动静脉移植物建立后的生存率相似。
J Vasc Surg. 2015 Dec;62(6):1590-7.e2. doi: 10.1016/j.jvs.2015.07.076. Epub 2015 Sep 12.
8
Inferiority of arteriovenous grafts, in comparison to autogenous fistulas, is underestimated by standard survival measures alone.与自体动静脉内瘘相比,动静脉移植物的劣势仅通过标准生存指标来衡量会被低估。
ANZ J Surg. 2021 Jan;91(1-2):162-167. doi: 10.1111/ans.16472. Epub 2020 Dec 8.
9
Effects of patient age on patency of chronic hemodialysis vascular access.患者年龄对慢性血液透析血管通路通畅率的影响。
BMC Nephrol. 2019 Nov 21;20(1):422. doi: 10.1186/s12882-019-1604-7.
10
Vascular access for hemodialysis in the elderly.老年患者血液透析的血管通路。
J Vasc Surg. 2019 Feb;69(2):517-525.e1. doi: 10.1016/j.jvs.2018.05.219.

引用本文的文献

1
Routine Clinic Surveillance on Arteriovenous Graft Patency in Hemodialysis Patients with Previous Access Complications.对既往存在血管通路并发症的血液透析患者动静脉移植物通畅情况的常规临床监测
Int J Med Sci. 2025 Feb 3;22(5):1064-1071. doi: 10.7150/ijms.106651. eCollection 2025.
2
Outcomes of arteriovenous graft vs. fistula for haemodialysis access in the elderly: A systematic review and meta‑analysis.老年患者血液透析通路中动静脉移植物与动静脉内瘘的疗效比较:一项系统评价和荟萃分析
Exp Ther Med. 2023 Jul 6;26(2):399. doi: 10.3892/etm.2023.12098. eCollection 2023 Aug.
3
Building a Scaffold for Arteriovenous Fistula Maturation: Unravelling the Role of the Extracellular Matrix.
构建动静脉瘘成熟的支架:解析细胞外基质的作用。
Int J Mol Sci. 2023 Jun 28;24(13):10825. doi: 10.3390/ijms241310825.
4
The challenging surgical vascular access creation.具有挑战性的外科血管通路建立。
Cardiovasc Diagn Ther. 2023 Feb 28;13(1):162-172. doi: 10.21037/cdt-22-560. Epub 2023 Feb 13.
5
Is the Fistula First Approach still valid?瘘管优先法是否仍然有效?
J Bras Nefrol. 2021 Apr-Jun;43(2):263-268. doi: 10.1590/2175-8239-JBN-2020-U001.